Risk Mitigation and Anomaly Detection: Managing Quality at Scale and Why AI Adoption Must Go Slow
Centaur Pharmaceuticals' VP Quality on the unique complexity of billion-tablet-scale pharma manufacturing, how AI can drive risk mitigation and anomaly detection, and why adoption must be incremental.
Vivek Gera Host
Co-founder · Leucine
Subhrangshu Chaudhary
VP Quality · Centaur Pharmaceuticals
About this episode
Vivek Gera speaks with Subhrangshu Chaudhary, VP Quality at Centaur Pharmaceuticals — overseeing operations at a facility producing 3.5 to 4 billion tablets annually — about what risk management looks like at a scale where pharmaceutical complexity has no analogue in other industries. Subhrangshu argues that unlike automobiles or electronics, pharmaceutical manufacturing cannot recall and replace a failed product: the mission is safe, effective medicine to sick patients, every time. The episode maps out the five areas where AI can add genuine value — process design, process control, monitoring and anomaly detection, predictive maintenance, and trend monitoring — and ends with a clear caution: pharma companies must evaluate their AI tools carefully, choose what fits their site and budget, and adopt incrementally rather than attempting systemic transformation all at once.
Topics
Key takeaways
- Pharmaceutical manufacturing complexity has no analogue in other industries — unlike cars or phones, a defective medicine cannot be recalled and replaced; the patient's life depends on getting it right the first time
- At billion-tablet scale, the challenge is not just manufacturing correctly but interpreting process data correctly: the data exists but identifying future failures before they surface remains an unsolved challenge
- AI delivers value in five distinct pharma domains: process design acceleration in R&D, real-time process control, monitoring and anomaly detection, predictive maintenance, and trend monitoring for quality signals
- Anomaly detection is where AI is most immediately actionable — identifying early signals in process data that human review would miss or only catch after a deviation has already been recorded
- The machinery of tablet production has not fundamentally changed; what has changed is the volume, regulatory complexity, and the burden of quality documentation — AI does not change the process but changes the intelligence layer on top of it
- Go slow on AI adoption: evaluate infrastructure readiness, choose tools that match site scale and budget, and upgrade people capabilities before expecting the technology to deliver results
Powered by
LeucineOS
See how an AI-native quality platform unifies QMS, compliance, and manufacturing operations.
Explore LeucineOSSee how Leucine's AI-native platform is transforming pharmaceutical quality and manufacturing operations.
